ID

28389

Beschreibung

Phase II Study of AS1411 Combined With Cytarabine to Treat Acute Myeloid Leukemia; Eligibility ODM derived from: https://clinicaltrials.gov/show/NCT00512083

Link

https://clinicaltrials.gov/show/NCT00512083

Stichworte

  1. 10.01.18 10.01.18 - Julian Varghese
  2. 10.01.18 10.01.18 - Stefan Hegselmann
Rechteinhaber

Mueller

Hochgeladen am

10. Januar 2018

DOI

Für eine Beantragung loggen Sie sich ein.

Lizenz

Creative Commons BY-NC 3.0

Modell Kommentare :

Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.

Itemgroup Kommentare für :

Item Kommentare für :

Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.

Eligibility Leukemia, Myeloid NCT00512083

Eligibility Leukemia, Myeloid NCT00512083

Inclusion Criteria
Beschreibung

Inclusion Criteria

Alias
UMLS CUI
C1512693
primary refractory or relapsed aml
Beschreibung

ID.1

Datentyp

boolean

Alias
UMLS CUI [1]
C0278780
confirmed diagnosis of aml (de novo or secondary) as defined by who classification (vardiman 2002)
Beschreibung

ID.2

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0023467
UMLS CUI [1,2]
C0011900
aged at least 18 years
Beschreibung

ID.3

Datentyp

boolean

Alias
UMLS CUI [1]
C0001779
Does the subject have an Eastem Cooperative Oncology Group (ECOG) Performance Status (PS) greater than 2?
Beschreibung

ECOG performance

Datentyp

boolean

Alias
UMLS CUI [1]
C1520224
Exclusion Criteria
Beschreibung

Exclusion Criteria

Alias
UMLS CUI
C0680251
initial diagnosis of acute promyelocytic leukemia as defined by french-american-british criteria (bennett 1976)
Beschreibung

ID.4

Datentyp

boolean

Alias
UMLS CUI [1]
C0023487
patient in blast crisis stage of chronic myeloid leukemia
Beschreibung

ID.5

Datentyp

boolean

Alias
UMLS CUI [1]
C0919644
received high-dose cytarabine (total cumulative dose of >6g/m sq)in last 6 months
Beschreibung

ID.6

Datentyp

boolean

Alias
UMLS CUI [1]
C0010711
interval of <6 months between first onset of last complete remission and current relapse
Beschreibung

ID.7

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0677874
UMLS CUI [1,2]
C0035020
those with primary refractory leukemia who have received more than three previous induction cycles
Beschreibung

ID.8

Datentyp

boolean

Alias
UMLS CUI [1,1]
C0857127
UMLS CUI [1,2]
C0392920
relapsed patients who have received more than three previous treatment regimens
Beschreibung

ID.9

Datentyp

boolean

Alias
UMLS CUI [1]
C0392920

Ähnliche Modelle

Eligibility Leukemia, Myeloid NCT00512083

Name
Typ
Description | Question | Decode (Coded Value)
Datentyp
Alias
Item Group
C1512693 (UMLS CUI)
ID.1
Item
primary refractory or relapsed aml
boolean
C0278780 (UMLS CUI [1])
ID.2
Item
confirmed diagnosis of aml (de novo or secondary) as defined by who classification (vardiman 2002)
boolean
C0023467 (UMLS CUI [1,1])
C0011900 (UMLS CUI [1,2])
ID.3
Item
aged at least 18 years
boolean
C0001779 (UMLS CUI [1])
ECOG performance
Item
Does the subject have an Eastem Cooperative Oncology Group (ECOG) Performance Status (PS) greater than 2?
boolean
C1520224 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
ID.4
Item
initial diagnosis of acute promyelocytic leukemia as defined by french-american-british criteria (bennett 1976)
boolean
C0023487 (UMLS CUI [1])
ID.5
Item
patient in blast crisis stage of chronic myeloid leukemia
boolean
C0919644 (UMLS CUI [1])
ID.6
Item
received high-dose cytarabine (total cumulative dose of >6g/m sq)in last 6 months
boolean
C0010711 (UMLS CUI [1])
ID.7
Item
interval of <6 months between first onset of last complete remission and current relapse
boolean
C0677874 (UMLS CUI [1,1])
C0035020 (UMLS CUI [1,2])
ID.8
Item
those with primary refractory leukemia who have received more than three previous induction cycles
boolean
C0857127 (UMLS CUI [1,1])
C0392920 (UMLS CUI [1,2])
ID.9
Item
relapsed patients who have received more than three previous treatment regimens
boolean
C0392920 (UMLS CUI [1])

Benutzen Sie dieses Formular für Rückmeldungen, Fragen und Verbesserungsvorschläge.

Mit * gekennzeichnete Felder sind notwendig.

Benötigen Sie Hilfe bei der Suche? Um mehr Details zu erfahren und die Suche effektiver nutzen zu können schauen Sie sich doch das entsprechende Video auf unserer Tutorial Seite an.

Zum Video